
## HALO

BIOPHARMACEUTICALS



# Increased Peak Capacity of Trastuzumab Tryptic Digest on PCS C18

#### **DIGESTION PROCEDURE:**

Standard digest conditions were used for an overnight digestion of trastuzumab drug product (stock concentration 21mg/mL) at 37 °C with shaking (final concentration 1.25µg mAb/µL). The sample buffer was 50mM ammonium bicarbonate. The sample was diluted with 50mM ABC to 1.5M Guanidine prior to trypsin digestion. The next day, the digest was adjusted to 0.5% formic acid prior to LCMS analysis. 2% ACN was added to the samplprior to analysis to aid solubility. The injected sample consisted of 1.5M guanidine HCl, 2% ACN, 0.5%Formic Acid, ~50mM Ammonium Bicarbonate, 1.25µg/µL digested mAb, 0.06µg/µL trypsin.

A separation of Trastuzumab tryptic digest is performed on two 160 Å HALO columns, the ES-C18 and PCS C18 phases. On the MS system a formic acid mobile phase is used in order to maintain high ionization efficiencies. Because of the use of a low ionic mobile phase additive (formic acid) separation of the digested mAb is difficult for the standard ES-C18 phase. By using a positively charged stationary phase (PCS C18) with low ionic condtions allows for an alternative selectivity and better separation of the peptides. By measuring peak width @ 50% of 3 distinct peptides it can be seen how the effect of the PCS C18 phase can significantly help peptide separations that require low ionic mobile phases such as formic acid.



Advancedmaterialstechnology Made in the USA I halocolumns.com

INNOVATION YOU CAN TRUST, PERFORMANCE YOU CAN RELY ON HALO® and Fused-Core® are registered trademarks of Advanced Materials Technology



HALO



#### **TEST CONDITIONS:**

Column: HALO 160 Å ES-C18 , 2.7 µm, 2.1 x 150 mm Part Number: 92122-702 Column: HALO 160 Å PCS-C18 , 2.7  $\mu m,$  2.1 x 150 mm Part Number: 92112-717 Mobile Phase A: Water + 0.1% Formic Acid Mobile Phase B: Acetonitrile + 0.1% Formic Acid Gradient: Time %B 0.0 3 30.0 50 30.1 95 33.0 95 33.1 3 37.0 3

### MS CONDITIONS:

System: QExactive HF ESI positive polarity 300-2000 m/z Source voltage: 3.2kV Sheath Gas: 40 Aux Gas: 20 Aus Gas Temp: 275°C Capillary Temp: 320°C µscans: 1 Max Injection Time: 200 msec S-Lens RF: 50

Flow Rate: 0.4 mL/min Pressure: 465 bar Temperature: 60 °C Injection Volume: 1 μL Sample: Trastuzumab Tryptic Digest (1.25 μg/μL) Sample Solvent: Refer to Digestion Procedure LC System: Shimadzu Nexera X2

Tubing Optimization:

Column outlet to Diverter Valve: AMT MarvelXACT<sup>™</sup> PEEKsil<sup>™</sup> 50 µm ID x 350 mm Part Number: PS7050350 Diverter Valve to Ground: AMT MarvelXACT<sup>™</sup> PEEKsil<sup>™</sup> 50 µm ID x 350 mm Part Number: PS7050350 Ground to Source: AMT MarvelXACT<sup>™</sup> PEEKsil<sup>™</sup> 50 µm ID x 150 mm Part Number: PS7050150



INNOVATION YOU CAN TRUST, PERFORMANCE YOU CAN RELY ON HALO® and Fused-Core® are registered trademarks of Advanced Materials Technology